• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Immunogenicity of a Monovalent A/H1pdm Vaccine with or without prior Seasonal Influenza Vaccine Administration

tetano

Editor, Senior Moderator
Clin Vaccine Immunol. 2012 Aug 1. [Epub ahead of print]
Immunogenicity of a Monovalent A/H1pdm Vaccine with or without prior Seasonal Influenza Vaccine Administration.
Igari H, Watanabe A, Segawa S, Suzuki A, Watanabe M, Sakurai T, Watanabe M, Tatsumi K, Nakayama M, Suzuki K, Sato T.
Source

Divisions of Control and Treatment of Infectious Diseases.
Abstract

The immunogenicity of A/H1pdm vaccine might be modified by prior seasonal trivalent influenza vaccine (sTIV). We conducted a retrospective analysis of immunogenicity of 243 health-care workers (sTIV+:216, sTIV-:27) by hemagglutination-inhibition. There was no significant difference in the ratio of antibody titers of >=40 (41.2% versus 48.1%; P=0.49) and factor increase in geometric mean titer (3.8 versus 4.5; P=0.37). sTIV injected 7-10 days prior to A/H1pdm vaccine did not interfere with the immunogenicity of the latter.

PMID:
22855394
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/22855394
 
Back
Top Bottom